ACCESS Newswire
23 Jan 2023, 18:49 GMT+10
SAN DIEGO, CA / ACCESSWIRE / January 23, 2023 / Ensysce Biosciences, Inc. ('Ensysce' or the 'Company') (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that Chief Executive Officer, Dr. Lynn Kirkpatrick, will present a company overview at the Diamond Equity Research 2023 Virtual Emerging Growth Invitational on Wednesday, January 25th, 2023, at 12:20 p.m. Eastern Time. Following the presentation, Dr. Kirkpatrick will take questions from participants.
Diamond Equity Research 2023 Virtual Emerging Growth Invitational
Date: Wednesday, January 25th, 2023
Time: 12:20 p.m. Eastern Time
Registration Link: Ensysce Biosciences, Inc. Diamond Equity Presentation
A live audio webcast and archive of the conference presentation will be available for a period of time using the registration link above. For more information on the Diamond Equity Research Emerging Growth Invitational, please contact your Diamond Equity Research representative or Ensysce's investor relations at [email protected].
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging TAAPTM and MPAR™, the Company is in the process of developing a unique, tamper-proof treatment option for pain that minimizes the risk of both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as 'may,' 'intends,' 'can,' 'might,' 'will,' 'expect,' 'plan,' 'possible,' 'believe' and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
MZ Group North America
Shannon Devine
203-741-8811
[email protected]
SOURCE: Ensysce Biosciences Inc.
Get a daily dose of Miami Mirror news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Miami Mirror.
More InformationMOSCOW, Russia: Russia's top oil company, Rosneft, has taken over control of the country's largest rare earth metals deposit, Tomtor,...
GOTHENBURG, Sweden: Volvo Cars is stepping up its collaboration with Google to become the lead development partner for Android automotive...
NEW YORK, New York - U.S. stock markets fell Friday as President Donald Trump launched an extraordinary attack on the European Union,...
SAN FRANCISCO, California: Levi Strauss is parting ways with Dockers. The denim giant announced this week that it will sell the Dockers...
OTTAWA, Canada: Canada's inflation picture became more complicated in April, with headline inflation easing but core measures ticking...
NEW YORK, New York - U.S. stocks had a volatile day on Thursday after the House of Representatives narrowly passed President Donald...
WASHINGTON, D.C.: The U.S. Transportation Department is expected to say that fuel economy rules created under President Joe Biden went...
WASHINGTON, D.C.: The U.S. Justice Department is investigating Andrew Cuomo, the former governor of New York and a top candidate for...
WASHINGTON, DC - U.S. President Donald Trump re-ignited his trade war on Friday with an extraordinary attack on the European Union...
ATLANTA, Georgia: A judge in Georgia has ruled that Delta Air Lines can continue most of its lawsuit against the cybersecurity company...
WASHINGTON, D.C.: U.S. senators from both parties introduced a bill this week aimed at countering China and Russia's growing influence...
NEW YORK CITY, New York: Officials are investigating why a Mexican Navy training ship hit the Brooklyn Bridge on May 17, breaking the...